ROG
$101.01
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components in the United States, other Americas, China, other Asia Pacific countries, Germany, Europe, the Middle East, and Africa.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components in the United States, other Americas, China, other Asia Pacific countries, Germany, Europe, the Middle East, and Africa. It operates in two Advanced Ele...
Recent News
Assessing Roche (SWX:ROG) Valuation After Recent Share Price Volatility And Obesity Drug Pipeline Update
Roche Holding: Recent Moves and What They Mean for Investors Roche Holding (SWX:ROG) has been on investors’ radar after recent share price swings, with the stock showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Roche Holding. At around CHF322.3 per share, Roche Holding’s recent 1-month share price return of a 10.47% decline contrasts with a positive 1-year total shareholder return of 10.30%. This suggests shorter term momentum has cooled while...
Roche Petrelintide Data Recasts Obesity Opportunity And Pipeline Growth Story
Roche Holding (SWX:ROG) reported highly positive Phase II results for its amylin analogue petrelintide in the ZUPREME-1 trial. The drug, co-developed with Zealand Pharma, achieved clinically meaningful and sustained weight loss in people living with overweight and obesity. Petrelintide showed a favorable tolerability profile, including fewer gastrointestinal side effects compared to placebo. The data support Roche’s plans for late-stage development and potential combination obesity...
Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study
Shares fell, wiping out year-to-date gains in the company’s stock after it said the combination of giredestrant with Pfizer’s Ibrance didn’t meet its primary objective.
Roche Obesity Trial Success Sparks Fresh Look At Valuation And Pipeline
Roche Holding (SWX:ROG) reported positive Phase II results from its ZUPREME-1 trial of petrelintide in obesity. The study showed meaningful weight loss and strong tolerability in participants. The data are seen as an important step for Roche's broader obesity pipeline and potential future combination therapies. For investors watching SWX:ROG, this update comes with the stock at around CHF341.2 and a 1 year return of 14.8%. The shares have seen a 44.4% return over 3 years and 32.2% over 5...
Pitney Bowes, Rogers, CRA, Exponent, and HNI Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after a dismal February jobs report revealed an unexpected drop in employment, fueling concerns about the health of the economy.